Management of non-alcoholic fatty liver disease

Bidragets oversatte titel: Nonalkoholisk fedtlever-sygdom ved overvægt og metabolisk syndrom

Camilla Dalby Hansen, Katrine Prier Lindvig, Henning Grønbæk, Lise Lotte Gluud, Maja Thiele, Aleksander Krag

Abstrakt

Non-alcoholic fatty liver disease (NAFLD) is the most frequent liver disease in the world, affecting 25% of the population. Around 6% of people with NAFLD will be at risk of developing advanced fibrosis, but symptoms often first occur very late from a decompensated cirrhosis. We need better referral pathways to identify and treat patients with advanced fibrosis. Non-invasive tests such as FIB-4 and NFS can be used in primary care to identify patients who will benefit from a referral to secondary care.

Bidragets oversatte titelNonalkoholisk fedtlever-sygdom ved overvægt og metabolisk syndrom
OriginalsprogEngelsk
TidsskriftUgeskrift for Laeger
Vol/bind184
Udgave nummer42
ISSN0041-5782
StatusUdgivet - 17 okt. 2022

Emneord

  • Humans
  • Non-alcoholic Fatty Liver Disease/diagnosis
  • Liver Cirrhosis/complications
  • Biopsy
  • Fibrosis
  • Referral and Consultation
  • Liver/pathology

Fingeraftryk

Dyk ned i forskningsemnerne om 'Nonalkoholisk fedtlever-sygdom ved overvægt og metabolisk syndrom'. Sammen danner de et unikt fingeraftryk.

Citationsformater